MIM. I. Ivanova

M. I. Ivanova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


M. I. Ivanova has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Correction of postoperative metabolic disorders after radiofrequency ablation for atrial fibrillation

    by M.I. Ivanova, V.M. Ivanov, A.YU. Petrov, A.L. Kovalenko, E.V. Talikova, K.V. Lenskaya

    Objective. To evaluate metabolic and neuroprotective properties of Cytoflavin in complex outpatient rehabilitation after radiofrequency ablation for atrial fibrillation. Material and methods. We analyzed the results of outpatient rehabilitation of 112 patients (50 men and 62 women, mean age 58.2±7.1 years) with paroxysmal atrial fibrillation after radiofrequency ablation. Patients were randomized into two groups: group I (main, n=59) — Cytoflavin (inosine+nicotinamide+riboflavin+succinic acid) prescribed in two-step scheme (20 ml intravenously in saline solution 200 ml for 10 days, then 2 tablets 2 times a day for 20 days); group II (comparison, n=53) — 10-day course of daily intravenous infusions of placebo 10 ml diluted in saline solution 200 ml followed by vitamin B12 (Vitamir) 1 tablet 1 time a day for 20 days. Cardiac parameters (echocardiography and ECG) and quality of life (HADS and MOS SF-36 questionnaires) were assessed before and after therapy. Results. Inclusion of Cytoflavin in outpatient rehabilitation therapy contributed to regression of ventricular hypertrophy (left by 1.2 times, right by 1.4 times) due to metabolic properties of this drug. Neuroprotective properties decreased anxiety by 5.3 times and depression by 1.7 times (HADS scale), as well as increased resistance to physical and emotional stress by 1.4 times (SF-36 scale). Conclusion. Inclusion of Cytoflavin in complex outpatient rehabilitation of patients with atrial fibrillation after radiofrequency ablation increases the effectiveness of treatment due to improvement of metabolic processes (reduction of atrial hypertrophy) and neuroprotective properties (reduction of anxiety and depression, increased resistance to physical and emotional stress). These data can be used for further studies.

  • Open Access

    Metabolic Therapy in Complex Rehabilitation of Patients After Radiofrequency Ablation

    by M. I. Ivanova, V. M. Ivanov, A. Yu. Petrov, A. L. Kovalenko, E. V. Talikova, K. V. Lenskaya

    The aim of the study was to evaluate the effectiveness of including the drug cytoflavin in the complex rehabilitation of patients after radiofrequency catheter ablation. Material and methods . The results of outpatient treatment of 112 patients after radiofrequency ablation associated with paroxysmal atrial fibrillation were analyzed. The subjects were randomized into two groups: in group 1 (main, N=59), in addition to standard therapy, the drug Cytoflavin (inosine+nicotinamide+riboflavin+succinic acid) was prescribed according to a two-step regimen: 20.0 ml intravenously by drip in 200 ml of 0.9% sodium chloride solution for 10 days, then 2 tablets 2 times a day for 20 days. In the 2nd group (comparison, N=53), in addition to standard therapy, patients received a ten-day course of daily intravenous drip infusions of 10 ml of placebo diluted in 200.0 ml of 0.9% sodium chloride solution, followed by eleutherococcus extract 100 mg, 2 tablets 2 times a day before meals, and combination preparations of B vitamins in the dosage recommended by the manufacturer. The psychoemotional state of patients (using the Hospital Anxiety and Depression Scale (HADS)) and quality of life with a point assessment of subjective characteristics (using the multi-purpose MOS SF-36 questionnaire) were studied dynamically (before and after rehabilitation). Results. The inclusion of cytoflavin in the regimens contributed to a more significant reduction in the severity of anxiety compared to the patients in the control group — 5.3 times, while in the control group the reduction amounted to only 1.75 times (P˂0.05), and signs of depression — 2 and 1.5 times, respectively (P˂0.05). The effectiveness of the presented outpatient treatment regimen was confirmed by the positive dynamics of patients' quality of life indicators on all SF-36 scales: the initial level of physical health of patients in group 1 increased from 69.8±13.2 to 85.6±4.2 (P˂0.05), and mental health — from 62.3±8.4 to 78.4±3.2 (P˂0.05), while in the comparison group — from 68.7±13.4 to 81.2±3.2 (P˂0.05) and from 61.4±7.3 to 71.3±2.2 (P˂0.05), respectively. Conclusion. The study showns the effectiveness of using Cytoflavin in the early restorative treatment of patients after radiofrequency catheter ablation, which is manifested by a more pronounced improvement in the psychoemotional state and quality of life of these patients.

  • Neuroprotection in outpatient treatment of post-covid syndrome

    by M. I. Ivanova, V. M. Ivanov V.M., A. L. Kovalenko, A. Yu. Petrov, E. V. Talikova

    The aim of the study was to investigate the effectiveness of including cytoflavin in the complex outpatient therapy of patients with post-COVID syndrome. Materials and methods: the results of outpatient treatment of 106 patients (49 men and 57 women, average age 52.4 ± 5.2 years) with post-COVID syndrome were analyzed. In addition to standard clinical and laboratory observation, the HADS scale was used to assess the severity of anxiety and depression, and the general clinical impression — CGI-S. Spirometry, Stange, and Genchi tests were used to assess the state of the respiratory system. Patients were randomly divided into two groups comparable in gender and age. The examination was carried out before the start of treatment and after the end of the course of therapy (on the 30th day). In the main group (I, n = 56), in addition to standard drug therapy, psychotherapy, exercise therapy and vacuum therapy on the thoracic and lumbar spine, cytoflavin was prescribed: 20.0 ml intravenously by drip in 200 ml of 0.9% sodium chloride solution for 10 days, then 2 tablets 2 times a day for 20 days. Patients in the comparison group (II, n = 50) received 10.0 ml of placebo diluted in 200.0 ml of 0.9% sodium chloride solution daily by intravenous drip, followed by taking the tablet form of vitamin B12 1 tablet 1 time per day for 20 days. Results: the inclusion of cytoflavin contributed to a more pronounced positive dynamics of clinical indicators (“chest pain” — 6 times in Group 1 and 2.2 times in the comparison group, “headaches” — 7 and 3 times, respectively, and “tachycardia” — 5.2 and 3 times, respectively (p < 0.01). Spirometry also revealed a more pronounced positive dynamics of external respiration indicators: deeper and slower breathing, relatively high ventilation reserve indicators, a longer time during the Stange and Gench tests. Against this background, a decrease in the level of anxiety and depression (according to the HADS scale) was noted: the frequency of recording atypical depressive symptoms decreased according to the “anxiety” indicator by almost 9 times in the main group and only 2.5 times in the comparison group, according to the “clinical depression” indicator — 12.5 and 5.5 times, respectively (p < 0.01). As a result, the majority (90.9%) of patients who received in the therapy scheme cytoflavin, the treatment was recognized as effective (according to the CGI scale). Conclusion. Тhe results obtained, along with good tolerability of the drug, allow us to recommend its use in outpatient complex therapy of patients with post-covid syndrome.

  • Neuroprotective component of outpatient rehabilitation of patients with lumbosciatica and depression

    by M. I. Ivanova, V. M. Ivanov, A. L. Kovalenko, A. Yu. Petrov, E. V. Talikova

    The aim of the study was to investigate the effectiveness of including cytoflavin in complex outpatient rehabilitation therapy for patients suffering from lumboschialgia and depression .Material and methods. 86 patients (38 men and 48 women, average age — 53.2 ± 5.9 years) with lumboschialgia and depression were examined. All patients underwent dynamic somatic and neurological status examination (before and after therapy), laboratory and instrumental studies were performed. To assess the neurological profile, the following were used: digital rating scale (DRS) of pain, Oswestry questionnaire (version 2.1a), hospital anxiety and depression scale (HADS), CGI-S scale, DN4 and SF-36 questionnaires. All patients underwent dynamic diagnostics of spinal mobility using the following parameters: Thomayer test (spinal flexion, distance floor – fingers (FF)), distance fingers legs (FL), backward bend while standing and lying on the stomach. In addition to standard treatment, patients in the main group (n = 44) were prescribed cytoflavin: 2 tablets 2 times a day regardless of food intake, 30-day course. The subjects from the control group (n = 42) received only standard treatment.Results. Inclusion of cytoflavin in the regimens contributed to a more pronounced reduction in pain syndrome compared to the control group: by 5 times according to the Oswestry questionnaire (version 2.1a), by 1.7 times versus 1.3 times according to the DN4 questionnaire, respectively (p < 0.05). The disappearance or significant reduction of pain syndrome contributed to the expansion of motor activity due to the increase in mobility in the spine — a more pronounced positive dynamics in terms of extension: 34.2 % and 22.9% in the main group versus 15.9% and 17.7% in the control group (p < 0.05). The inclusion of the drug contributed to a more significant reduction in neurological symptomatology disorders than in patients in the control group: anxiety indicators (according to the HADS scale) in the control group decreased by 5.3 times, while in the control group they decreased only by 1.75 times (p < 0.05); signs of depression — by 2 and 1.5 times, respectively (p < 0.05). At the same time, the subjects to a greater extent noted a decrease in fatigue, an improvement in night sleep, an increase in activity and performance. The effectiveness of the presented outpatient rehabilitation scheme was confirmed by the positive dynamics of the patients’ quality of life indicators on all SF-36 scales: the most significant increase on the scales of “role functioning due to physical condition” and “pain intensity” — on average by 25.9 points in the control and 26.3 points in the main, respectively (p ≥ 0.05).Conclusion. The inclusion of cytoflavin in the complex treatment of patients with this pathology helps to reduce the intensity of pain, increase spinal mobility and eliminate the neuropathic component, which improves the quality of life of patients. The results obtained can serve as a basis for further research in this area.

  • The possibilities of accompanying therapy for malignant oropharyngeal neoplasms

    by M.I. Ivanova, G.G. Matyakin, V.M. Ivanov, M.V. Sheikin, A.L. Kovalenko, A.YU. Petrov

    ЦЕЛЬ ИССЛЕДОВАНИЯ Оценка эффективности включения ремаксола в схему сопроводительной терапии пациентов со злокачественными новообразованиями орофарингеальной области с проявлениями токсических реакций на этиотропное лечение. МАТЕРИАЛ И МЕТОДЫ Проведен анализ данных 104 пациентов (88 мужчин и 16 женщин) с P-отрицательным раком ротоглотки T3-4 N0-3 M0. Все больные получали этиотропную терапию по комбинированной схеме. У всех присутствовали признаки токсических реакций местного (оральный мукозит, ксеростомия) и общего (гепатотоксичность) характера, в связи с чем этим пациентам была назначена терапия сопровождения. В зависимости от этого больные были разделены на две группы: основную (n=62) составили получившие 400 мл ремаксола внутривенно со скоростью 40—80 капель/мин (2—4 мл/мин) 1 раз в сутки в течение 10 дней. Пациенты 2-й группы (контрольная/сравнения, n=42) получили внутривенно капельно 400 мл глюкозоэлектролитной смеси 1 раз в сутки также в течение 10 дней. Состояние оценивали по клинико-лабораторным показателям и результатам тестирования по индексу Карновского, шкале ECOG и OHIP-14. РЕЗУЛЬТАТЫ Включение ремаксола в схемы сопроводительной терапии у пациентов со злокачественными новообразованиями орофарингеальной области и токсическими реакциями на этиотропную терапию повысило эффективность лечения: снижалась выраженность токсических реакций (орального мукозита, ксеростомии и гепатотоксичности) и повышались показатели качества жизни пациентов. ЗАКЛЮЧЕНИЕ Полученные результаты и хорошая переносимость препарата позволяют рекомендовать его для включения в схемы терапии пациентов с этой патологией.


  • Role of meglumine sodium succinate in the prevention of cardiotoxicity induced by chemoradiotherapy in patients with breast cancer

    by M.I. Ivanova, G.G. Matyakin, V.M. Ivanov, A.L. Kovalenko, O.V. Ivanova

    ЦЕЛЬ ИССЛЕДОВАНИЯ Изучение эффективности включения в схему терапии сопровождения 1,5% раствора меглюмина натрия сукцината у больных раком молочной железы. МАТЕРИАЛ И МЕТОДЫ Проанализированы результаты лечения 127 больных с местно-распространенным первично неоперабельным раком молочной железы IIIA степени. В зависимости от схемы терапии сопровождения они были разделены на две группы: основная (1-я, n=64) — пациентки в процессе лечения получали 1,5% раствор меглюмина натрия сукцината: 500 мл внутривенно капельно, курс 10 дней. В группе сравнения (2-я, n=63) больные получили адеметионин: 400 мл внутривенно капельно, курс 10 дней. Пациентки были обследованы в динамике в соответствии с принятыми стандартами. РЕЗУЛЬТАТЫ И ОБСУЖДЕНИЕ Через 1 мес от начала терапии у всех пациенток была отмечена положительная динамика клинических (уменьшение кардиальной симптоматики) и инструментальных данных (по данным ЭКГ и ЭхоКГ). Это способствовало повышению качества жизни больных (шкалы ECOG-WHO и SF=36) и было обусловлено кардиопротективным действием назначенных препаратов. При этом у пациенток, получавших меглюмина натрия сукцинат, выявлена более выраженная положительная динамика клинико-инструментальных данных. ЗАКЛЮЧЕНИЕ Полученные данные позволяют рекомендовать включение меглюмина натрия сукцината в терапию сопровождения у пациенток с данной патологией.